Colistin Loading Dose in Septic Patients with Gram Negative Infections

References

• Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200–211. doi:10.1016/S0140-6736(19)32989-7
   PubMed Web of Science ®Google Scholar
• Mae E-SA, Zhong LL, Shen C, Yang Y, Doi Y, Tian GB. Colistin and its role in the Era of antibiotic resistance: an extended review (2000-2019). Emerg Microbes Infect. 2020;9(1):868–885. doi:10.1080/22221751.2020.1754133
   Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333–1341. doi:10.1086/429323
   PubMed Web of Science ®Google Scholar
• Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–377. doi:10.1007/s00134-017-4683-6
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39. doi:10.1002/phar.2209
   PubMed Web of Science ®Google Scholar
• Nazer LH, Anabtawi N. Optimizing colistin dosing: is a loading dose necessary? Am J Health Syst Pharm. 2017;74(1):e9–e16. doi:10.2146/ajhp150876
   Web of Science ®Google Scholar
• Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54(12):1720–1726. doi:10.1093/cid/cis286
   PubMed Web of Science ®Google Scholar
• Dalfino L, Puntillo F, Ondok MJ, et al. Colistin-associated acute kidney injury in severely ill patients: a step toward a better renal care? A prospective cohort study. Clin Infect Dis. 2015;61(12):1771–1777. doi:10.1093/cid/civ717
   PubMed Web of Science ®Google Scholar
• Trifi A, Abdellatif S, Daly F, et al. Efficacy and toxicity of high-dose colistin in multidrug-resistant Gram-negative bacilli infections: a comparative study of a matched series. Chemotherapy. 2016;61(4):190–196. doi:10.1159/000442786
   PubMed Web of Science ®Google Scholar
• Elefritz JL, Bauer KA, Jones C, Mangino JE, Porter K, Murphy CV. Efficacy and safety of a colistin loading dose, high-dose maintenance regimen in critically ill patients with multidrug-resistant Gram-negative pneumonia. J Intensive Care Med. 2017;32(8):487–493. doi:10.1177/0885066616646551
   PubMed Web of Science ®Google Scholar
• ICD-10-CM Diagnosis Code. Available from: https://www.icd10data.com/ICD10CM/Codes/A00-B99/A30-A49/A41-/A41.9. Accessed December 31, 2021.
   Google Scholar
• Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31. doi:10.1186/cc5713
   PubMed Web of Science ®Google Scholar
• Moni M, Sudhir AS, Dipu TS, et al. Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant Gram-negative bacterial infections: a prospective observational study. Int J Infect Dis. 2020;100:497–506. doi:10.1016/j.ijid.2020.08.010
   PubMed Web of Science ®Google Scholar
• Gibson GA, Bauer SR, Neuner EA, Bass SN, Lam SW. Influence of colistin dose on global cure in patients with bacteremia due to carbapenem-resistant Gram-negative bacilli. Antimicrob Agents Chemother. 2016;60(1):431–436. doi:10.1128/AAC.01414-15
   PubMed Web of Science ®Google Scholar
• Katip W, Meechoui M, Thawornwittayakom P, Chinwong D, Oberdorfer P. Efficacy and safety of high loading dose of colistin in multidrug-resistant Acinetobacter baumannii: a prospective cohort study. J Intensive Care Med. 2019;34(11–12):996–1002. doi:10.1177/0885066617725694
   PubMed Web of Science ®Google Scholar
• Jung S, Chung EK, Jun MS, Son ES, Rhie SJ. Differences in colistin administration and bacterial and treatment outcomes in critically ill patients. Sci Rep:8781. Sci Rep. 2019;9(1):8781. doi:10.1038/s41598-019-44965-y
   Web of Science ®Google Scholar
• Bellos I, Pergialiotis V, Frountzas M, Kontzoglou K, Daskalakis G, Perrea DN. Efficacy and safety of colistin loading dose: a meta-analysis. J Antimicrob Chemother. 2020;75(7):1689–1698. doi:10.1093/jac/dkaa064
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Rellos K, Triarides NA, Falagas ME. Colistin loading dose: evaluation of the published pharmacokinetic and clinical data. Int J Antimicrob Agents. 2016;48(5):475–484. doi:10.1016/j.ijantimicag.2016.08.009
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010;35(2):194–199. doi:10.1016/j.ijantimicag.2009.10.005
   PubMed Web of Science ®Google Scholar
• Van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2018;66(2):163–171. doi:10.1093/cid/cix783
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K pneumoniae. Clin Infect Dis. 2019;68(3):355–364. doi:10.1093/cid/ciy492
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and Safety of meropenem-Vaborbactam versus Best-available Therapy in Patients with carbapenem-Resistant Enterobacteriaceae Infections: the TANGO II Randomized Clinical Trial. Infect Dis Ther. 2018;7(4):439–455. doi:10.1007/s40121-018-0214-1
   PubMed Web of Science ®Google Scholar
• Doi Y. Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin Infect Dis. 2019;69(Suppl 7):S565–S575. doi:10.1093/cid/ciz830
   PubMed Web of Science ®Google Scholar